MONTREAL and CHARLOTTE, N.C., May 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of
Growth Capitalist (https://growthcapitalist.com/2019/05/milestone-pharmaceuticals-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-in-its-initial-public-offering/)
MONTREAL and CHARLOTTE, N.C., May 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of